PTPRC and chronic kidney disease: Two of those studies that were conducted in toxic CKD have performed immunostaining in kidney tissue of NGS mice, to report that the animals receiving EV-based therapy had a significantly lower expression of CD45 positive cells, FSP-1 and α-SMA positive myofibroblasts.